New A/H1N1 vaccines developed by Thai research team

Dr. Anan Jongkaewwattana, Head of BIOTEC Virology and Cell Technology Laboratory, and his team have successfully generated seed vaccines using genetic materials of the novel human influenza virus, A/Nonthaburi/102/2009 (H1N1), isolated from the country's first confirmed patient. The seed viruses are generated based on the genetic constellation of the first candidate vaccine, so-called NYMC-179A, announced by US-CDC in May. Instead of using classical egg-based selection method, Anan has employed reverse genetics technology to construct a "5+3" reassortant virus that can grow efficiently in embryonated chicken eggs. The seed virus has also been developed, also by reverse genetics, as live-attenuated vaccine by Dr. Prasert Auewarakul and Dr. Onpreeya Saptaveewat of Siriraj Hospital.

Both seed vaccines will be tested for the safety and immunogenicity in ferrets, which can take from 2-3 months before they can be mass produced.


Dr. Anan Jongkaewwattana (center) with his team at BIOTEC Virology and Cell Technology Laboratory



Posted on 14 July 2009.